The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
SGB-3908 for sc injection
Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered
Peking University Third Hospital
Beijing, Beijing Municipality, China
Number of Participants with Adverse Events (AEs)
Time frame: up to approximately 12 months
Change from Baseline in Blood Angiotensinogen (AGT) Level
Time frame: up to approximately 12 months
Maximum Observed Plasma Concentration (Cmax) of SGB-3908 and of Potential Metabolites
Time frame: Up to Day 3
Area Under the Concentration-time Curve (AUC) of SGB-3908 and of Potential Metabolites
Time frame: Up to Day 3
Number of Participants With Anti- SGB-3908 Antibodies
Time frame: up to approximately 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.